Featured Article
FDA's Investigation of Gabapentinoid Abuse Stirs Controversy Among Pain Management Specialists
FDA's Investigation of Gabapentinoid Abuse Stirs Controversy Among Pain Management Specialists

The FDA's recent announcement of a new enquiry into the risks of abuse of gabapentinoids has generated a flock of comments from doctors - some pro and some con. Gabapentin and pregabalin are collectively referred to as "gabapentinoids." Pregabalin is marketed as Lyrica and ...

Read More

Recent News

  • Safe opioid disposal offered by retailers and drugmaker

    A couple of retail pharmacies and even a drug manufacturer are making it easier for patients to safely get rid of leftover opioids. Properly disposing ...

    View More
  • Announcing New Novus Detox Center in West Palm Beach

    Now Taking Patients at Our New Detox Center in West Palm Beach! Novus Medical Detox Centers® is proud to announce the opening of our newest Detox ...

    View More
  • New Opioid Funding is a Welcome Start, But More Will Be Needed

    A $6 billion boost to fight the opioid epidemic - $3 billion in 2018 and $3 billion in 2019 - was a highlight of the 2-year, $400 billion federal ...

    View More
  • In the Media: Kent Runyon Discussing the Opioid Crisis on Bay News Channel 9 Tampa Bay

    Novus Detox VP of Community Relations, Kent Runyon, went on Bay News Channel 9 Tampa Bay to discuss the opioid crisis. “We had a homeless 18-year-old ...

    View More
  • Purdue Pharma to Stop Marketing Oxycontin to Doctors in the United States

    After suffering years of massively negative public relations and countless lawsuits for its role in helping create the opioid epidemic, Purdue Pharma ...

    View More
  • In the Media: Kent Runyon on WFLA Discussing the Opioid Addiction Crisis

    Novus VP of Community Relations Kent Runyon discussed how the opioid addiction crisis is affecting people in Florida and across the United States on ...

    View More
  • FDA, FTC crack down on unapproved opioid addiction, withdrawal meds

    The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have sent joint warning letters to a dozen makers, marketers and ...

    View More
  • DEA Relaxes Buprenorphine Prescribing Rules to Boost Rural Opioid Addiction Treatment

    The U.S. Drug Enforcement Administration (DEA) has "deregulated" some restrictions on who is allowed to prescribe buprenorphine, to help expand the ...

    View More
  • Novus Set to Open Second Facility in West Palm Beach Later This Month

    Novus Detox held a ribbon cutting ceremony for its newest location in West Palm Beach on Thursday, February 1, set to officially open its doors later ...

    View More

Start Your New Path to Sobriety Today!

    • Please enter your name.
    • This isn't a valid phone number.
    • Please enter your email address.
      This isn't a valid email address.
    • Please make a selection.
    • Please enter a message.